Tanios S. Bekaii-Saab, MD, on Genomic Drivers in Cholangiocarcinoma at ASCO 2021

Video

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma. Notably, cholangiocarcinoma is a genomically diverse disease, with 2 main drivers that have current FDA-approved targeted agents.

Transcript:

Biliary tract cancers are very interesting, especially intrahepatic cholangiocarcinoma; we are seeing more of this strictly [in] extrahepatic cholangiocarcinoma [and] even gallbladder. This disease is so anatomically diverse, but also genomically very diverse. We just recently started to break down the disease by site [and], more importantly, by genomic driver. In intrahepatic cholangiocarcinoma, there are 2 main drivers that we know of that now have either a drug [approval] or [one that is] on its way to possibly being approved.

For FGFR fusions, we know now that we have 2 agents approved. That [represents] about 10% to 15% of all patients with intrahepatic cholangiocarcinoma. To put that again in perspective, we are talking about 3000 to 5000 patients a year in the United States. That is a rare patient population that we are splitting into pieces. The FGFR-targeted agents are pemigatinib [Pemazyre] and infigratinib [(Truseltiq); those are the 2 drugs] approved for that space. Now, it turns out that there is another target that is very interesting, [which] is essentially an IDH mutation. Without really going through a lot of the biology, IDH1/2 is a key enzyme in cellular metabolism epigenetic regulation.

Reference

Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): a comprehensive genomic and immune profiling study. J Clin Oncol. 2021;39(suppl 15):4009. doi:10.1200/JCO.2021.39.15_suppl.4009

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Related Content